Differential effects of REV-ERBα/β agonism on cardiac gene expression, metabolism, and contractile function in a mouse model of circadian disruption

• Published in: American journal of physiology. Heart and circulatory physiology 2020-06, Vol.318 (6), p.H1487-H1508
• Main Authors: Mia, Sobuj, Kane, Mariame S, Latimer, Mary N, Reitz, Cristine J, Sonkar, Ravi, Benavides, Gloria A, Smith, Samuel R, Frank, Stuart J, Martino, Tami A, Zhang, Jianhua, Darley-Usmar, Victor M, Young, Martin E
• Format: Article
• Language: English
• Subjects: Animals; ARNTL Transcription Factors - metabolism; Circadian Clocks - physiology; Circadian Rhythm - drug effects; Circadian Rhythm - physiology; Gene Expression; Gene Expression Regulation; Heart - drug effects; Mice; Mice, Knockout; Myocardium - metabolism; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Nuclear Receptor Subfamily 1, Group D, Member 1 - agonists; Pyrrolidines - pharmacology; Thiophenes - pharmacology
• ISSN: 0363-6135; 1522-1539
• DOI: 10.1152/ajpheart.00709.2019

Cell-autonomous circadian clocks have emerged as temporal orchestrators of numerous biological processes. For example, the cardiomyocyte circadian clock modulates transcription, translation, posttranslational modifications, ion homeostasis, signaling cascades, metabolism, and contractility of the heart over the course of the day. Circadian clocks are composed of more than 10 interconnected transcriptional modulators, all of which have the potential to influence the cardiac transcriptome (and ultimately cardiac processes). These transcriptional modulators include BMAL1 and REV-ERBα/β; BMAL1 induces REV-ERBα/β, which in turn feeds back to inhibit BMAL1. Previous studies indicate that cardiomyocyte-specific BMAL1-knockout (CBK) mice exhibit a dysfunctional circadian clock (including decreased REV-ERBα/β expression) in the heart associated with abnormalities in cardiac mitochondrial function, metabolism, signaling, and contractile function. Here, we hypothesized that decreased REV-ERBα/β activity is responsible for distinct phenotypical alterations observed in CBK hearts. To test this hypothesis, CBK (and littermate control) mice were administered with the selective REV-ERBα/β agonist SR-9009 (100 mg·kg ·day for 8 days). SR-9009 administration was sufficient to normalize cardiac glycogen synthesis rates, cardiomyocyte size, interstitial fibrosis, and contractility in CBK hearts (without influencing mitochondrial complex activities, nor normalizing substrate oxidation and Akt/mTOR/GSK3β signaling). Collectively, these observations highlight a role for REV-ERBα/β as a mediator of a subset of circadian clock-controlled processes in the heart.